Notice: ASA extends its thoughts and condolences to those affected by the disaster in Oklahoma. Donations to help aid this relief can be made through the American Red Cross website.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 20, 2013

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility: Recall - Lack Of Sterility Assurance

Summary:

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

Frequently Asked Questions About the “Company Model”

Wednesday, June 20, 2012

On June 1, 2012, the Department of Health and Human Services Office of Inspector General (HHS-OIG) issued an Advisory Opinion (No. 12-06) on a "company model" arrangement and expressed the view that it could violate the federal anti-kickback statute. 

In order to provide assistance to our members, ASA has created an FAQ document with answers to some of the most frequently asked questions regarding the “company model” and the Advisory Opinion.  The document will be updated as warranted.

Review ASA’s FAQs.

Review the HHS-OIG Advisory Opinion.

« Back to Washington Alerts